e-Edition
Obituaries
Special Sections
Special Occasions
Contact
Subscribe
Paywall Login
Login to Comment
Register
December 11th, 2017
jobs
homes
Menu
Home
News
Sports
Business
Entertainment
Classifieds
Commentary
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Biohaven Ltd. Common Shares
(NY:
BHVN
)
8.370
-0.550 (-6.17%)
Official Closing Price
Updated: 7:00 PM EDT, Mar 27, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biohaven Ltd. Common Shares
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
Where Biohaven Pharma Hldgs Stands With Analysts
↗
August 03, 2021
Within the last quarter, Biohaven Pharma Hldgs (NYSE:BHVN) has observed the ...
Via
Benzinga
The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs
↗
July 30, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
Stocks That Hit 52-Week Highs On Thursday
↗
July 29, 2021
Thursday's morning session saw 167 companies set new 52-week highs. Points of Interest: ASML Holding (NASDAQ:ASML) was the largest company by market cap to set a new...
Via
Benzinga
Analyst Ratings For Biohaven Pharma Hldgs
↗
July 16, 2021
Analysts have provided the following ratings for Biohaven Pharma Hldgs (NYSE:
Via
Benzinga
Analyst Ratings For Biohaven Pharma Hldgs
↗
July 12, 2021
Analysts have provided the following ratings for Biohaven Pharma Hldgs (NYSE:
Via
Benzinga
Analyst Ratings For Biohaven Pharma Hldgs
↗
July 08, 2021
Within the last quarter, Biohaven Pharma Hldgs (NYSE:BHVN) ...
Via
Benzinga
The Daily Biotech Pulse: FDA Nod For Merck-Eisai, Seres' Ulcerative Colitis Drug Flunks Midstage Study, Pfizer To Invest In Arvinas, AbSci IPO
↗
July 22, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 21) Biohaven Pharmaceutical...
Via
Benzinga
Will This Biopharma Company Continue to Crush It?
↗
July 17, 2021
Migraine sufferers certainly hope so.
Via
The Motley Fool
10 Biggest Price Target Changes For Monday
↗
July 12, 2021
RBC Capital boosted Chipotle Mexican Grill, Inc. (NYSE:C...
Via
Benzinga
The Daily Biotech Pulse: J&J, Novartis Report Solid Results, Chembio Soars On COVID Test Order, Lumos Signals Clinical Trial Delay
↗
July 21, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 20) Alnylam Pharmaceuticals,...
Via
Benzinga
Biohaven Rallies On Preliminary Nurtec Revenue Numbers: What Investors Need To Know
↗
July 07, 2021
Biohaven Pharmaceutical Ltd. (NYSE:BHVN) released preliminar...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
July 07, 2021
Gainers Opiant Pharmaceuticals (NASDAQ:OPNT
Via
Benzinga
The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues
↗
July 14, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 13) Biohaven Pharmaceutical...
Via
Benzinga
Here's Why Biohaven Pharmaceutical Is Soaring Today
↗
July 07, 2021
Preliminary sales figures for the company's new migraine drug were much better than expected.
Via
The Motley Fool
The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO
↗
July 09, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8) Aerpio Pharmaceuticals, Inc...
Via
Benzinga
The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test
↗
July 08, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) Ambrx Biopharma Inc. (NYSE:...
Via
Benzinga
Topics
Product Recall
61 Biggest Movers From Yesterday
↗
July 08, 2021
Gainers Newegg Commerce, Inc. (NASDAQ: NEGG) shares surged 148.4% to close at $67.57 on Wednesday after jumping around 42% on Tuesday. Mannatech, Incorporated (NASDAQ: MTEX)...
Via
Benzinga
Jim Cramer Says People Need To Know About Biohaven
↗
July 07, 2021
Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) announced...
Via
Benzinga
Biohaven Stock Hits Record High As Migraine Drug Trounces Quarterly Forecasts
↗
July 07, 2021
Biohaven crushed Wall Street's expectations for second-quarter sales of migraine drug Nurtec on Tuesday, leading BHVN stock to pop.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
July 07, 2021
Gainers Dare Bioscience (NASDAQ:DARE) shares increased by 51.97% to $2.31 during Wednesday's pre-market session. The market value of their outstanding shares is at $...
Via
Benzinga
The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend
↗
July 07, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 6) Ambrx Biopharma Inc. (NYSE:...
Via
Benzinga
Biohaven Pharmaceutical: Return On Capital Employed Insights
↗
June 23, 2021
During Q1, Biohaven Pharmaceutical's (NYSE:BHVN) reported sales totaled $43.82 million. Despite a 28.93% in earnings, the company posted a loss of $235.88 million. In Q4, Biohaven...
Via
Benzinga
Eli Lilly To Test Injectable Migraine Med Against Biohaven's Oral Nurtec In Head-To-Head Study
↗
June 15, 2021
Eli Lilly And Co (NYSE: LLY) will conduct a head-to-head study comparing once-monthly injectable Emgality (galcanezumab-gnlm) with Biohaven Pharmaceutical...
Via
Benzinga
Biotechs Ready To Roar
↗
June 13, 2021
The biggest event last week was the FDA decision to approve Biogen's drug aducanumab, a treatment for Alzheimer's disease. The decision will reverberate across the industry and the healthcare sector...
Via
Talk Markets
Biotech Movers During ASCO Week
↗
June 12, 2021
The biotech sector performed well in a good ASCO week. And many biotech stocks were movers this week as a bullish sentiment took hold sparked by the Biogen Aduhelm approval.
Via
Talk Markets
The Daily Biotech Pulse: Vertex Shelves Mid-Stage Study, Precigen & Novan Jump On Data, Hematology Conference, Janux Debuts
↗
June 11, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 10) Alexion Pharmaceuticals,...
Via
Benzinga
Photo of Biohaven Pharmaceuticals Ringing the Opening Bell Available on Business Wire's Website and the Associated Press Photo Network
June 08, 2021
From
Biohaven Pharmaceuticals
Via
Business Wire
Biohaven Pharmaceutical Insights: Return On Capital Employed
↗
June 07, 2021
In Q1, Biohaven Pharmaceutical (NYSE:BHVN) posted sales of $43.82 million. Earnings were up 28.93%, but Biohaven Pharmaceutical still reported an overall loss of $235.88 million....
Via
Benzinga
Analyst Ratings for Biohaven Pharma Hldgs
↗
June 01, 2021
Analysts have provided the following ratings for Biohaven Pharma Hldgs (NYSE:BHVN) within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 0 2...
Via
Benzinga
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
↗
May 31, 2021
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-...
Via
Benzinga
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.